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ABSTRACT 
Background
Frailty and Parkinson’s disease (PD) are both highly prevalent 
in older people, but few studies have studied frailty in people 
with Parkinson’s. Identifying frailty in this population is vital, 
to target new interventions to those who would most benefit. 
Methods
Data were collected as part of the double-blind randomised 
controlled rivastigmine to stabilise gait ReSPonD trial in 130 
people with Hoehn and Yahr 2-3, idiopathic PD who had fallen 
in the year prior to enrolment. Individuals were assessed at 
baseline and followed up at eight months, including deter-
mination of frailty status.     
Results
120 patients attended for follow-up. At follow-up, the mean 
(SD) age was 70.2 years (8.0), MDS-UPDRS total score 91.5 
(29.1), and MDS-UPDRS motor score (Part III) 42.7 (14.8). 
Median disease duration was 9.2 years (IQR 4.6 to 13.1), 
Geriatric Depression Score 4 (IQR 2 to 6). Using the Fried 
frailty criteria, 31 (26%) were frail and 70 (58%) pre-frail. In 
univariable analysis, being female, higher depression score, 
and MDS-UPDRS score  were associated with greater frailty. 
Using ordinal regression, in the multivariable model, being 
female (odds ratio [OR] 3.10, 95%CI 1.53 to 6.26, p=.002), 
higher total MDS-UPDRS score (OR 2.02, 95%CI 1.42 to 2.87, 
p<.0001) and higher depression (OR 1.47, 95%CI 1.05 to 2.06, 
p=.03) were associated with higher number of frailty markers. 
Conclusion
There was a high prevalence (84%) of pre-frail and frail indi-
viduals in patients participating in this RCT. Future research 
should determine the optimum tool to assess frailty in this 
at-risk population, and delineate the association between 
Parkinson’s, frailty, and health outcomes.   
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INTRODUCTION 
Frailty and Parkinson’s disease (PD) are conditions that are 
highly prevalent in older people, and share common features. 
However, few studies have described frailty in people with 
Parkinson’s.
Frailty is recognised as a state of increased vulnerability 
to stressors through loss of physiological reserve and function.
(1) Whilst it has eluded a consensus definition,(2) there have 
been two approaches to quantifying frailty. The phenotype 
model first developed by Fried(3) defines frailty as the presence 
of three or more out of five criteria: weakness, weight loss, 
slow walking speed, fatigue, and low physical activity. An 
alternative approach proposed by Rockwood and Mitniski(4) 
measures acquired deficits of symptoms, diseases, and dis-
ability to describe an overall frailty burden. This is expressed 
as an index measure, but has subsequently been developed 
into more usable clinical scales.(5)   
The pathophysiology of frailty is not fully understood, 
but it is thought that chronic inflammation and immune 
system activation result in multisystem dysfunction af-
fecting the musculoskeletal, endocrine, haematological, 
and cardiovascular systems.(6) Reserve is diminished, such 
that the body becomes incapable of adapting to acute and 
chronic stressors. The aetiology of PD is similarly not fully 
understood, but immune system activation, oxidative stress, 
abnormal protein processing, and mitochondrial disrup-
tion converge and contribute to the complex cascade of 
dysfunction that result in cell loss in the substantia nigra, 
dopamine deficiency in the neostriatum, and disruption of 
other neurotransmitter pathways.(7,8) PD confers an increased 
risk of various negative health outcomes, including falls,(9) 
fractures, and cognitive impairment.(10)
Frailty and PD are clinical syndromes resulting from 
multisystem disorders which result in increased vulnerability 
to stressors. Identifying frailty in this population may offer 
an opportunity to identify those at increased risk of negative 
outcomes and, thus, intervene to reduce the mortality and 
morbidity associated with both conditions.(11)
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METHODS
Population
Data for this analysis were collected as part of the ReSPonD 
trial, a double-blind randomised controlled trial of rivastig-
mine vs. placebo to stabilise gait in people with PD, the 
methods of which have been previously described.(12,13) One 
hundred and thirty people were enrolled at a single UK site, 
with Hoehn and Yahr stage 2–3 idiopathic PD. All participants 
had fallen in the last year, could walk 18 metres unaided, 
and had been stable on anti-Parkinsonian medication for two 
weeks prior to enrolment. Patients were excluded if they had 
neurological, visual, or orthopaedic problems that interfered 
with balance or gait, were non-English speaking, or had 
PD-dementia. Ethical approval was granted from the South 
West Central Bristol Research Ethics Committee and written 
informed consent was obtained from participants.
Procedure
Frailty status was determined at a 32-week follow-up visit, 
using the original 5 Fried criteria.(3) The following informa-
tion was collected to determine the frailty score: 1) Weakness, 
measured as a grip strength below published cutoffs;(3) 2) Slow 
walking speed, below published cutoffs;(3) 3) Self-reported 
weight loss of >4.5 kg in the past year; 4) Self-reported exhaus-
tion, measured using two questions from the Centre for Epi-
demiological Studies Depression Scale;(14) and 5) Low physical 
activity, defined as those scoring in the lowest quintile on the 
Physical Activity Scale for the Elderly (PASE; Low score <52 
for women and <64 for men).(15) A score of 3 or more features 
were defined as frailty, while the presence of 1 or 2 factors in-
dicated pre-frailty. Those with 0 frailty features were defined as 
non-frail. Duration of PD was defined as years since diagnosis. 
Patients were assessed using the Movement Disorders Society 
Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), 
which ranges from 0 to 265, with higher score indicating greater 
disease severity. They also completed the Geriatric Depression 
Scale, which scores people’s mood, with higher scores indicat-
ing greater depressive symptoms (range 0 to 15).
Statistical Analysis
Baseline data are described as mean ± Standard Deviation 
(SD) if normally distributed or as median interquartile range 
(25th percentile, 75th percentile) if skewed. We used ordinal 
logistic regression to look at the association between de-
mographic factors and PD factors, and number of positive 
frailty criteria. Stata/MP 15.1 was used to perform statistical 
analysis. We analysed both the MDS-UPDRS and depres-
sion scale as continuous variables. However, we tested the 
linearity assumption by creating an ordinal variable (tertiles) 
and repeating our models using both ordinal and nominal cat-
egories to compare the effect estimates. As these appeared to 
be consistent with a linear pattern, we have used the original 
continuous variable in the final models. We standardised both 
variables in our analysis (z-scored), to facilitate the description 
of the effects on frailty.
RESULTS 
One hundred and thirty participants were enrolled in the study, 
of which 120 attended for the 32-week follow-up assessment. 
Of the 10 lost to follow-up, 3 died, 4 withdrew, and 3 were 
too unwell to attend. 
Table 1 presents the demographic data of the patients 
included. 37.5% were women. At follow-up, the mean age 
was 70.2 years (SD 8.0), MDS-UPDRS total score 91.5 (SD 
29.1), and mean MDS-UPDRS Part III (motor score) 42.7 
(14.8). Median disease duration was 9.2 years (IQR 4.6 to 
13.1), Geriatric Depression Score 4 (IQR 2 to 6). Using the 
Fried frailty criteria, n=31 individuals (26%) scored as frail, 
with 3 or more positive frail criteria, and 70 (58%) were pre-
frail, as they had 1 or 2 features. 
In univariable analysis, being female, higher depression 
score and higher MDS-UPDRS score were associated with 
greater number of frailty criteria (all p values <.05). Age was 
included in the univariate model, but did not reach signifi-
cance and was therefore not included in the final model. In the 
multivariable ordinal logistic model (n=120), we found that 
being female (OR 3.10, 95%CI 1.53 to 6.26, p = .002), higher 
total MDS-UPDRS score (OR 2.02, 95%CI 1.42 to 2.87, p < 
.0001), and higher depression score (OR 1.47, 95%CI 1.05 to 
2.06, p = .03) were associated with higher number of frailty 
markers (see Table 2).  
TABLE 1.  
Demographic data for patients attending follow-up visita
Number (%) of women 45 (37.5%)
Number (%) of men 75 (62.5%)
Age (yrs) 70.2 (8)
IQR for age (yrs) 65.4 – 75.9
Median (IQR) Montreal Cognitive 
Assessment score
25 (22.5-27)
Median (IQR) Geriatric Depression Scale 
score
4 (2 to 6 )
MDS-UPDRS score (SD) 91.5 (29.1)
Part III MDS-UPDRS score (SD) 42.7 (14.8)
Median (IQR) years since Parkinson’s 
disease diagnosis 
9.2 (4.6 to 13.1)
Number of frail patients 31 (26%)
Number of pre-frail patients 70 (58%)
Number of non-frail patients 19 (16%)
Fried Frailty Criteria
Number of weak patients 61 (50.8%)
Number of slow patients 17 (14.1%)
Number of patients with weight loss 26 (21.7%)
Number of exhausted patients 66 (55%)
Number of inactive patients 33 (27.5%)
aData are presented as mean (SD) unless stated. 
MDS-UPDRS = Movement Disorders Society Unified Parkinson’s 
Disease Rating Scale; IQR = inter-quartile range.
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DISCUSSION
In this study of 120 ambulatory patients with well-controlled 
PD who had fallen in the past year, we found that frailty 
was highly prevalent, with 26% classified as frail, and 58% 
pre-frail. This estimate exceeds that which we would have 
expected in a non-PD population of similar age,(16) consistent 
with previous research suggesting PD patients have higher 
frailty rates.(17,18) 
Our study included a selected trial population, and may 
not be generalizable to the wider population of PD with early 
or very advanced disease. Our study sample also had a rela-
tively narrow range of ages, which may explain why no effect 
was seen for age on frailty. Given that our participants had a 
history of past fall(s), we will have excluded earlier milder 
cases of PD who would be expected to have less frailty, and 
hence these results may have over-estimated frailty rates in 
the broader PD population. However, our study excluded 
participants who could not walk 18 metres without an aid, 
which will counter this bias to some degree in the opposite 
direction so that our results would be better than expected. 
These results confirm a high pre-frailty rate in this PD 
population despite only moderate length disease duration 
(median 9.2 years). Identification of pre-frailty is attractive 
because it may offer an opportunity to intervene before a 
frailty syndrome is fully established and decompensation 
might be irreversible. Our findings, that patients with higher 
MDS-UPDRS scores have more positive frailty criteria, also 
aligns with previous research.(17) Accurately identifying the 
two clinical syndromes in at-risk patients is crucial, as the 
presence of frailty may be misidentified as a decline in PD. 
This growing evidence of higher frailty in patients with 
PD, as well as research identifying similar inflammatory 
processes occurring in both frailty and PD, have prompted 
suggestions of a shared pathophysiology between frailty, PD, 
and ageing.(17,18,19) Large longitudinal cohort studies study-
ing the onset and progression of PD and frailty would help 
inform whether one precedes the other, or if the two, at least 
for some patients share a pathogenesis. 
We have shown that the Fried frailty model can easily 
be applied to PD patients, and is useful in identifying frailty 
and pre-frailty. The model has its weaknesses, notably its 
exclusive focus on physical attributes, which neglects the 
psychosocial elements of frailty. Its approach to categorising 
continuous variables, which are dichotomised according to a 
cut-off, also risks potentially losing valuable data. Although 
simple in its categorisation of individuals, it cannot be used 
to differentiate between different degrees of frailty. Several 
of the Fried criteria also overlap with motor and non-motor 
symptoms of PD (e.g., slow walking, fatigue) and, therefore, 
risk over-diagnosing frailty in people with PD. This would 
depend on whether age-related frailty phenotypes have the 
same significance as disease-related features. There is in-
creasing recognition that refining the approach to measuring 
frailty is necessary. The more comprehensive frailty models, 
such as electronic frailty indices(20) or the SHARE frailty 
instrument,(21) include deficits in multiple domains, and may 
thereby better reflect the complexity of the frailty syndrome. 
Other measures can be more easily applied in clinical set-
tings—such as the nine-point Clinical Frailty Scale which 
incorporates pictographs(5)—can be used with relatively little 
training, and does not focus exclusively on physical frailty.
CONCLUSION
We found a high prevalence of pre-frailty and frailty in patients 
with PD who had a history of having fallen. Future research 
should use representative longitudinal cohorts, studying the 
onset and progression of PD and frailty, as this would help 
delineate unique and overlapping aspects of pathogenesis. 
This would also usefully inform which tool is optimal to as-
sess frailty in this vulnerable population.
ACKNOWLEDGEMENTS
The ReSponD trial in which this study was nested was funded 
by a Parkinson’s UK career development award (F1003) 
awarded to Emily J. Henderson. The funder had no role in 
the study design or writing of the report.
CONFLICT OF INTEREST DISCLOSURES
The authors declare that no conflicts of interest exist.
TABLE 2. 
Univariable and multivariable regression analysis of relationship between gender,  













Female gender 2.25 1.14, 4.43 0.019 3.10 1.53, 6.26 .002
MDS-UPDRS (z-score) 1.97 1.41, 2.76 <.0001 2.02 1.42, 2.87 <.001
GDS (z-score) 1.64 1.18, 2.28 .003 1.47 1.05, 2.06 .03
aOdds ratio for one standard deviation increase from the mean for UPDRS and GDS.
MDS-UPDRS = Movement Disorders Society Unified Parkinson’s Disease Rating Scale; GDS = Geriatric Depression Scale; SD = standard deviation. 
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